Leadership

The Architects.

AI expertise meets medical device excellence. A rare combination for a unique challenge.

Board of Directors

Strategic oversight and capital allocation.

Sam Errama

Chairman

Platform architecture and AI strategy. Drives board-level decisions on technology roadmap, regulatory posture, and capital deployment.

Taha Errama

Director

Governance and technology oversight across the hardware, optical, and AI stack.

Aman Samuel Abraham

Director

Commercial and strategic governance. Aligns product roadmap with hospital adoption and OEM partnership pathways.

Executive Team

The team that built the system is the team commercializing it.

Christophe Bailleul

VP Clinical and QA/RA

Clinical development, quality management, and regulatory affairs. Owns the 510(k) path for the AI Engine, the IDE trial protocol, and the medical device quality system.

Focus:

Clinical trial design and execution
FDA 510(k) and EU MDR pathways
Medical device quality management system

Lucía Colmenero

Finance Director

Financial operations, capital deployment, and human resources. Manages the runway model for the Series A and the build-out of clinical and engineering hiring.

Focus:

Corporate finance and planning
Capital deployment against the €25M plan
Talent acquisition and operations

Clinical Advisors

Cardiac electrophysiology leadership from McGill, Imperial, Sunnybrook, and CHU Rennes. Advisory relationships in transition as of the Series A.

Prof. Atul Verma, MD

Director of Cardiology, McGill University Health Centre

300+ peer-reviewed publications including NEJM. Led STAR AF II. Principal Investigator of the AblaView® first-in-human study (Europace, 2025).

Prof. Raphaël Martins, MD, PhD

Cardiac Electrophysiologist, CHU Rennes / University of Rennes

AF mechanisms and translational ablation research. Co-investigator on the AblaView® FIM study. Active in major multicentre EP trials.

Dr. Maria Terricabras, MD

Cardiac EP and Director, Preclinical Cardiovascular Lab, Sunnybrook / U of Toronto

Specialist in preclinical evaluation of novel ablation devices. Lead author of the AblaView® PS-OCR study (Circulation, 2024). Assistant Professor, University of Toronto.

Prof. Sabine Ernst, MD, PhD

Professor of Practice, Imperial College London / Royal Brompton Hospital

Pioneered remote magnetic navigation and performed the first fully remote catheter ablation globally in 2003. Research lead in EP at Royal Brompton. 200+ publications.

Why This Team Wins

Most medical device companies lack AI expertise. Most AI companies lack medical device experience. AblaView® has both.

We bridge the gap between cutting-edge machine learning and the rigorous safety requirements of the cardiac cath lab.